Virology
NS5A protein confers a multiplicative advantage to hepatitis C virus
Published in Hepatitis Weekly, August 30th, 2004
According to published research from France, "hepatitis C virus infection (HCV) is a major cause of liver disease worldwide, and is frequently resistant to interferon-alpha treatment. The nonstructural (NS) 5A protein of HCV has been proposed to be involved in this resistance. Additional studies have pointed out a role for NS5A in several other cellular interactions as well as an important role of its adaptative mutations in HCV genome replication."
"However, no infectious system is available to assess the role of NS5A in the HCV life cycle. Thus, we have constructed a recombinant...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-08-30)
More Articles from Hepatitis Weekly
- Chronic Hepatitis C
Pegylated interferon and ribavirin cures many with hepatitis C virus infection - Immunology
Tests for anti-E2 antibody enhance hepatitis C detection in dialysis patients - Renal Transplant
Ultralow-dose interferon plus ribavirin helps HCV-positive kidney recipients - Transfusion Medicine
Blood donation may be a source of hepatitis E virus transmissions in Japan - Business & Finance
LymphoStat-B maker reports losses, milestones in Q2 2004 - Carcinogenesis
Fumonisin B-1 encourages liver disease and liver cancer formation - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
